Invivyd (NASDAQ: IVVD) posts preliminary Q4 2025 revenue data and updates

Rhea-AI Filing Summary

Invivyd, Inc. filed a current report describing a new press release that shares preliminary fourth quarter 2025 PEMGARDA® (pemivibart) net product revenue and the company’s cash and cash equivalents as of December 31, 2025. These figures are early management estimates and may change after Invivyd completes its financial closing procedures and finalizes its audited financial statements for the quarter and full year 2025.

The company explains that the preliminary data have not been audited by its independent registered public accounting firm and that additional information will be needed for a full picture of its financial position and results of operations. Invivyd also filed the full press release as an exhibit and made an updated corporate presentation available on its website, providing investors with recent business highlights alongside the early financial indicators.

Insights

Equity research analyst

Invivyd shares unaudited Q4 2025 revenue and cash estimates.

Invivyd, Inc. released preliminary fourth quarter 2025 net product revenue for PEMGARDA® and an estimate of cash and cash equivalents as of December 31, 2025. These numbers are positioned as early indicators of commercial performance and liquidity heading into the company’s year-end reporting.

The company emphasizes that the figures are management estimates, subject to change after completion of financial closing controls and external audit work. This caveat means the information provides directional insight but not final results. The updated corporate presentation filed as an exhibit and posted online consolidates these preliminary metrics with wider business highlights, giving the market an early look ahead of the full year 2025 financial statements.

false 0001832038 0001832038 2026-01-08 2026-01-08

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): January 8, 2026

Invivyd, Inc.

(Exact Name of Registrant as Specified in its Charter)

Delaware		001-40703		85-1403134
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

209 Church Street New Haven, CT		06510
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (781) 819-0080

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, par value $0.0001 per share		IVVD		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On January 8, 2026, Invivyd, Inc. (the “Company”) issued a press release entitled “Invivyd Reports Preliminary Fourth Quarter 2025 Revenue and Recent Business Highlights” (the “Press Release”), which included the Company’s estimated fourth quarter 2025 PEMGARDA^® (pemivibart) net product revenue and cash and cash equivalents as of December 31, 2025. The amounts included in the Press Release are preliminary and are subject to change upon completion of the Company’s financial closing controls and procedures for the quarter and year ended December 31, 2025, and finalization of the Company’s financial statements. The preliminary financial data included in the Press Release have been prepared by, and are the responsibility of, the Company’s management. These preliminary estimates have not been audited by the Company’s independent registered public accounting firm. Additional information and disclosures would be required for a more complete understanding of the Company’s financial position and results of operations as of December 31, 2025. A copy of the Press Release is filed herewith as Exhibit 99.1 and is incorporated by reference in this Item 2.02.

Item 8.01 Other Events.

On January 8, 2026, the Company issued the Press Release, a copy of which is filed herewith as Exhibit 99.1 and is incorporated by reference in this Item 8.01.

On January 8, 2026, the Company posted an updated corporate presentation on its website at www.invivyd.com. A copy of the presentation is filed herewith as Exhibit 99.2 and is incorporated by reference in this Item 8.01.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release, dated January 8, 2026
99.2		Corporate Presentation, dated January 8, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				INVIVYD, INC.
Date: January 8, 2026				By:		/s/ Jill Andersen
						Jill Andersen
						Chief Legal Officer and Corporate Secretary

FAQ

What did Invivyd (IVVD) disclose in this Form 8-K?

Invivyd reported that it issued a press release containing preliminary fourth quarter 2025 PEMGARDA® net product revenue, cash and cash equivalents as of December 31, 2025, and recent business highlights.

Are Invivyd’s preliminary Q4 2025 financial figures final?

No. Invivyd states the preliminary revenue and cash figures are management estimates that are subject to change after completion of financial closing controls, procedures, and finalization of its financial statements.

Has Invivyd’s independent auditor reviewed the preliminary data?

Invivyd explains that the preliminary financial data included in the press release have not been audited by its independent registered public accounting firm.

Where can investors find Invivyd’s detailed preliminary Q4 2025 information?

The detailed preliminary figures and business highlights are included in a press release filed as Exhibit 99.1 and in an updated corporate presentation filed as Exhibit 99.2 and posted on Invivyd’s website.

What product does Invivyd highlight in its preliminary Q4 2025 revenue update?

Invivyd highlights PEMGARDA® (pemivibart), noting estimated fourth quarter 2025 net product revenue for this therapy in the press release.

Does this 8-K include Invivyd’s full 2025 financial statements?

No. The company notes that additional information and disclosures will be required for a more complete understanding of its financial position and results of operations as of December 31, 2025.